Benzinga | Apr 29, 2021 07:05AM EDT

AtriCure's EPi-Sense System Approved by FDA for Treatment of Long-Standing Persistent Afib Patients

FDA approval results in the only label of its kind for more than 3 million patients in the United States, significantly expanding AtriCure's addressable market

Superiority trial showed a 29% difference in effectiveness at 12 months and a 35% difference in effectiveness at 18 months for long-standing persistent Afib patients.

Study also showed improved Electrophysiology Lab efficiency